Integer (ITGR) Expected to Announce Earnings on Thursday

Integer (NYSE:ITGR) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, April 24th. Analysts expect the company to announce earnings of $1.28 per share and revenue of $428.51 million for the quarter. Integer has set its FY 2025 guidance at 5.840-6.200 EPS.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. On average, analysts expect Integer to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Integer Stock Performance

NYSE:ITGR opened at $118.12 on Wednesday. The firm has a market capitalization of $4.12 billion, a PE ratio of 35.16, a PEG ratio of 1.72 and a beta of 1.09. Integer has a 1 year low of $104.93 and a 1 year high of $146.36. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The firm’s fifty day simple moving average is $120.73 and its 200 day simple moving average is $130.42.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ITGR. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Truist Financial lowered their price objective on shares of Integer from $163.00 to $140.00 and set a “buy” rating on the stock in a research note on Friday, April 11th. KeyCorp cut their target price on shares of Integer from $154.00 to $145.00 and set an “overweight” rating for the company in a research note on Monday. Benchmark raised their price target on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Finally, Raymond James assumed coverage on shares of Integer in a research report on Friday, March 28th. They set an “outperform” rating and a $145.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $145.00.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.